GlassScriptPhysician profile
Chasity Downey
NPI 1275954695
$2,815.87
in general payments reported to CMS, 2019-2025
20 companies · $743 in 2025
The $743 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.70 · 2022: $21.11 · 2023: $1,154 · 2024: $880 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,416.19 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $176.03 | 2023-2024 | Xarelto |
| Medtronic, INC. | $153.71 | 2025 | Venaseal |
| Boston Scientific Corporation | $148.37 | 2023-2024 | Watchman Flx, Bodyguardian |
| Tactile Systems Technology INC | $115.75 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Actelion Pharmaceuticals US, INC. | $113.72 | 2023-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $96.30 | 2023-2025 | Verquvo |
| Amgen INC. | $89.20 | 2024-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals, LTD. | $77.81 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $72.71 | 2024 | Assure Wcd |
| Philips North America LLC | $57.01 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Pfizer INC. | $56.12 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.20 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.29 | 2023-2025 | Jardiance |
| Azurity Pharmaceuticals, INC. | $41.28 | 2023-2025 | Edarbi, Edarbyclor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $36.81 | 2023-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $19.90 | 2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $19.23 | 2023 | |
| Organogenesis INC. | $17.47 | 2025 | Simplimax |
| Astrazeneca Pharmaceuticals LP | $13.77 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chasity Downey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.